Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
216 studies found for:    "methodist hospital" | Open Studies | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury
Condition: Spinal Cord Injury
Intervention:
2 Not yet recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific CTLs
3 Recruiting Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Hydroxytyrosol
4 Recruiting TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: TDM1;   Drug: Lapatinib;   Drug: Abraxane
5 Recruiting PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anthracycline based chemotherapy;   Drug: taxane-based chemotherapy
6 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel
7 Recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Condition: Colorectal Cancer
Interventions: Drug: celecoxib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
8 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
9 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
10 Recruiting The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery
Conditions: Heart Failure;   Ventricular Dysfunction
Interventions: Device: CoSeal;   Device: BioGlue® Surgical Adhesive
11 Recruiting ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus
Condition: Viral Infection
Intervention: Biological: Multi-virus-specific cytotoxic T lymphocytes
12 Recruiting Specific Cytotoxic T-Lymphocytes, EBV-positive Lymphoma, GRALE
Conditions: Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Lymphoproliferative Disease;   Lymphoma
Interventions: Biological: LMP, BARF1 & EBNA1 specific CTLs: A;   Biological: LMP, BARF1 & EBNA1 specific CTLs : B
13 Recruiting Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Conditions: Acute Lymphoblastic Leukemia (ALL);   Chronic Lymphocytic Leukemia (CLL);   Non Hodgkin's Lymphoma
Intervention: Genetic: CD19CAR/virus specific T cells
14 Recruiting CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
Condition: Glioblastoma Multiforme (GBM)
Intervention: Genetic: Genetically modified HER.CAR CMV-specific CTLs
15 Recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
16 Recruiting Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma
Intervention: Drug: CAR.CD30 T cells
17 Recruiting Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Biological: Antigen Escalation Stage;   Biological: Dose escalation study of T cells
18 Not yet recruiting MOST CLOSELY MATCHED 3RD PARTY RAPIDLY GENERATED LMP, BARF1 and EBNA1 SPECIFIC CTL, EBV-POSITIVE LYMPHOMA
Conditions: Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
Intervention: Biological: MABEL CTLs
19 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
20 Recruiting iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS
Condition: Sarcomas
Interventions: Genetic: GD2 T cells;   Biological: VZV vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years